Cargando…
Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons
Pathogenic heterozygous variants in SCN2A, which encodes the neuronal sodium channel Na(V)1.2, cause different types of epilepsy or intellectual disability (ID)/autism without seizures. Previous studies using mouse models or heterologous systems suggest that Na(V)1.2 channel gain-of-function typical...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281746/ https://www.ncbi.nlm.nih.gov/pubmed/37010102 http://dx.doi.org/10.1093/hmg/ddad048 |
_version_ | 1785061056173834240 |
---|---|
author | Asadollahi, R Delvendahl, I Muff, R Tan, G Rodríguez, D G Turan, S Russo, M Oneda, B Joset, P Boonsawat, P Masood, R Mocera, M Ivanovski, I Baumer, A Bachmann-Gagescu, R Schlapbach, R Rehrauer, H Steindl, K Begemann, A Reis, A Winkler, J Winner, B Müller, M Rauch, A |
author_facet | Asadollahi, R Delvendahl, I Muff, R Tan, G Rodríguez, D G Turan, S Russo, M Oneda, B Joset, P Boonsawat, P Masood, R Mocera, M Ivanovski, I Baumer, A Bachmann-Gagescu, R Schlapbach, R Rehrauer, H Steindl, K Begemann, A Reis, A Winkler, J Winner, B Müller, M Rauch, A |
author_sort | Asadollahi, R |
collection | PubMed |
description | Pathogenic heterozygous variants in SCN2A, which encodes the neuronal sodium channel Na(V)1.2, cause different types of epilepsy or intellectual disability (ID)/autism without seizures. Previous studies using mouse models or heterologous systems suggest that Na(V)1.2 channel gain-of-function typically causes epilepsy, whereas loss-of-function leads to ID/autism. How altered channel biophysics translate into patient neurons remains unknown. Here, we investigated iPSC-derived early-stage cortical neurons from ID patients harboring diverse pathogenic SCN2A variants [p.(Leu611Valfs*35); p.(Arg937Cys); p.(Trp1716*)] and compared them with neurons from an epileptic encephalopathy (EE) patient [p.(Glu1803Gly)] and controls. ID neurons consistently expressed lower Na(V)1.2 protein levels. In neurons with the frameshift variant, Na(V)1.2 mRNA and protein levels were reduced by ~ 50%, suggesting nonsense-mediated decay and haploinsufficiency. In other ID neurons, only protein levels were reduced implying Na(V)1.2 instability. Electrophysiological analysis revealed decreased sodium current density and impaired action potential (AP) firing in ID neurons, consistent with reduced Na(V)1.2 levels. In contrast, epilepsy neurons displayed no change in Na(V)1.2 levels or sodium current density, but impaired sodium channel inactivation. Single-cell transcriptomics identified dysregulation of distinct molecular pathways including inhibition of oxidative phosphorylation in neurons with SCN2A haploinsufficiency and activation of calcium signaling and neurotransmission in epilepsy neurons. Together, our patient iPSC-derived neurons reveal characteristic sodium channel dysfunction consistent with biophysical changes previously observed in heterologous systems. Additionally, our model links the channel dysfunction in ID to reduced Na(V)1.2 levels and uncovers impaired AP firing in early-stage neurons. The altered molecular pathways may reflect a homeostatic response to Na(V)1.2 dysfunction and can guide further investigations. |
format | Online Article Text |
id | pubmed-10281746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102817462023-06-21 Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons Asadollahi, R Delvendahl, I Muff, R Tan, G Rodríguez, D G Turan, S Russo, M Oneda, B Joset, P Boonsawat, P Masood, R Mocera, M Ivanovski, I Baumer, A Bachmann-Gagescu, R Schlapbach, R Rehrauer, H Steindl, K Begemann, A Reis, A Winkler, J Winner, B Müller, M Rauch, A Hum Mol Genet Original Article Pathogenic heterozygous variants in SCN2A, which encodes the neuronal sodium channel Na(V)1.2, cause different types of epilepsy or intellectual disability (ID)/autism without seizures. Previous studies using mouse models or heterologous systems suggest that Na(V)1.2 channel gain-of-function typically causes epilepsy, whereas loss-of-function leads to ID/autism. How altered channel biophysics translate into patient neurons remains unknown. Here, we investigated iPSC-derived early-stage cortical neurons from ID patients harboring diverse pathogenic SCN2A variants [p.(Leu611Valfs*35); p.(Arg937Cys); p.(Trp1716*)] and compared them with neurons from an epileptic encephalopathy (EE) patient [p.(Glu1803Gly)] and controls. ID neurons consistently expressed lower Na(V)1.2 protein levels. In neurons with the frameshift variant, Na(V)1.2 mRNA and protein levels were reduced by ~ 50%, suggesting nonsense-mediated decay and haploinsufficiency. In other ID neurons, only protein levels were reduced implying Na(V)1.2 instability. Electrophysiological analysis revealed decreased sodium current density and impaired action potential (AP) firing in ID neurons, consistent with reduced Na(V)1.2 levels. In contrast, epilepsy neurons displayed no change in Na(V)1.2 levels or sodium current density, but impaired sodium channel inactivation. Single-cell transcriptomics identified dysregulation of distinct molecular pathways including inhibition of oxidative phosphorylation in neurons with SCN2A haploinsufficiency and activation of calcium signaling and neurotransmission in epilepsy neurons. Together, our patient iPSC-derived neurons reveal characteristic sodium channel dysfunction consistent with biophysical changes previously observed in heterologous systems. Additionally, our model links the channel dysfunction in ID to reduced Na(V)1.2 levels and uncovers impaired AP firing in early-stage neurons. The altered molecular pathways may reflect a homeostatic response to Na(V)1.2 dysfunction and can guide further investigations. Oxford University Press 2023-04-03 /pmc/articles/PMC10281746/ /pubmed/37010102 http://dx.doi.org/10.1093/hmg/ddad048 Text en © The Author(s) 2023. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Asadollahi, R Delvendahl, I Muff, R Tan, G Rodríguez, D G Turan, S Russo, M Oneda, B Joset, P Boonsawat, P Masood, R Mocera, M Ivanovski, I Baumer, A Bachmann-Gagescu, R Schlapbach, R Rehrauer, H Steindl, K Begemann, A Reis, A Winkler, J Winner, B Müller, M Rauch, A Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons |
title | Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons |
title_full | Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons |
title_fullStr | Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons |
title_full_unstemmed | Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons |
title_short | Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons |
title_sort | pathogenic scn2a variants cause early-stage dysfunction in patient-derived neurons |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10281746/ https://www.ncbi.nlm.nih.gov/pubmed/37010102 http://dx.doi.org/10.1093/hmg/ddad048 |
work_keys_str_mv | AT asadollahir pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT delvendahli pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT muffr pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT tang pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT rodriguezdg pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT turans pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT russom pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT onedab pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT josetp pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT boonsawatp pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT masoodr pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT moceram pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT ivanovskii pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT baumera pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT bachmanngagescur pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT schlapbachr pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT rehrauerh pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT steindlk pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT begemanna pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT reisa pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT winklerj pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT winnerb pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT mullerm pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons AT raucha pathogenicscn2avariantscauseearlystagedysfunctioninpatientderivedneurons |